Gonadotrophin-releasing hormone analogues: a novel treatment for premenstrual asthma

Premenstrual exacerbation of asthma, as reflected by a reduction in peak es piratory flow rate (PEFR), has been demonstrated in 40-100% of female asthm atics. Epidemiological data demonstrate that admission to hospital with an exacerbation of asthma occurs more frequently perimenstrually: Therapeutic interventions aimed at modifying this precipitating factor, however, remain limited. We report on a 32-yr old female with asthma in whom a marked increase in sy mptoms and reduction in PEFR occurred premenstrually; necessitating recurre nt admissions to hospital. Frequent severe exacerbations resulted in the ch ronic use of oral maintenance corticosteroids. In order to suppress gonadot rophin secretion and ovarian function, a long-acting gonadotrophin-releasin g hormone analogue aas administered with a view: to inducing a reversible m enopause. This resulted in improvement in respiratory symptoms, the absence of PEFR dips premenstrually a reduction in maintenance prednisolone dosage and no further hospital admissions during a follow-up period of 14 months. The authors propose that gonadotrophin-releasing hormone-analogue therapy i s a rational and innovative adjuvant treatment worthy of further study in c ases of severe premenstrual asthma.